Overview

MK-2206 in Recurrent Nasopharyngeal Carcinoma

Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the activity and safety of MK-2206 in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC)
Phase:
Phase 2
Details
Lead Sponsor:
Chinese University of Hong Kong